MARKET

IMUX

IMUX

Immunic Inc
NASDAQ
1.190
0.000
0.00%
After Hours: 1.200 +0.01 +0.84% 19:51 04/08 EDT
OPEN
1.220
PREV CLOSE
1.190
HIGH
1.250
LOW
1.180
VOLUME
1.31M
TURNOVER
--
52 WEEK HIGH
1.510
52 WEEK LOW
0.5062
MARKET CAP
155.25M
P/E (TTM)
-1.9067
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMUX last week (0330-0403)?
Weekly Report · 2d ago
Immunic Files Prospectus To Offer Up To 458.2M Shares Of Common Stock By The Selling Stockholders
Benzinga · 6d ago
IMMUNIC INC - TO OFFER UP TO 458.2 MLN SHARES OF COMMON STOCK REGISTERED FOR RESALE BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
Reuters · 04/01 16:14
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Reuters · 04/01 13:14
Immunic Regains Nasdaq Compliance, Stabilizing Listing Status
TipRanks · 04/01 12:55
BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks
Reuters · 04/01 11:40
BUZZ-Immunic rises as regains Nasdaq listing compliance
Reuters · 04/01 10:36
More
About IMUX
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.

Webull offers Immunic Inc stock information, including NASDAQ: IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.